CliffBio
biologic

Soliris

eculizumab

Loss of exclusivityMarch 2019projected — 12-year biologic exclusivity estimate
CompanyAlexion Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameSoliris
Active ingredienteculizumab
Strength300MG/30ML (10MG/ML)
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalMarch 2007
Marketing statusRx

More from Alexion Pharmaceuticals

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Soliris patent cliff — loss of exclusivity March 2019 | CliffBio